Search companies on Owler
Advanced Search
Latest news
Newsfeed
My followed companies
Followed Companies
609 Followers on Owler
OverviewCompetitorsAcquisitionsFundingNews & Insights

NexImmune

NexImmune researches, develops and commercializes T cell-based immunotherapies for the treatment of cancer. Read more

Scott P. Carmer's photo - CEO of NexImmune

CEO

Scott P. Carmer

CEO Approval Rating

85/100

Founded:

2011

Status:

PublicIndependent CompanyNASDAQNEXI

SIC Code:

2836 NAICS listing »

2834 NAICS listing »

Website:

Annual Revenue
Employees
Sector
Biotechnology
Pharmaceuticals
Headquarters

NEXIMMUNE TOP COMPETITORS OR ALTERNATIVES

RANK

COMPANY

CEO

CEO RATING

EMPLOYEES

FUNDING

REVENUE

Missing a competitor? Contribute!

The top 10 competitors in NexImmune's competitive set are BMS, Novartis, Gilead, Aura Biosciences, Juno Therapeutics, Perthera, bluebird bio, Centrose, Jounce, VelosBio. Together they have raised over 15.2B between their estimated 191.9K employees. NexImmune has 44 employees and is ranked 14th among it's top 10 competitors. The top 10 competitors average 9,657.

BMS is NexImmune's #1 competitor. BMS's headquarters is in New York, New York, and was founded in 1858. Like NexImmune, BMS also works within the Biotechnology sector. BMS generates ∞% of NexImmune's revenue.

Novartis is one of NexImmune's top rivals. Novartis was founded in Basel, Basel-City} in 1996. Novartis operates in the Pharmaceuticals industry. Compared to NexImmune, Novartis generates $48.8B more revenue.

Gilead is one of NexImmune's top competitors. Gilead is a Public company that was founded in 1987 in Foster City, California. Gilead is in the Pharmaceuticals industry. Compared to NexImmune, Gilead has 13,556 more employees.

Weigh-in!

Help the Owler community know more

Competitor - 1/1

Is Juno Therapeutics a competitor of NexImmune?

I don't know

Trending News for NexImmune and NexImmune's Competitors

June 12, 2021

Pharmabiz

Bristol Myers Squibb announces positive results from phase 3 TRANSFORM study of Breyanzi versus chemotherapy followed by stem cell transplant in secondline r/r LBCL

Bristol Myers Squibb announced positive topline results from TRANSFORM, a global, randomized, multice... See more »

June 12, 2021

Pharmabiz

US FDA approves Gilead's new formulation of Epclusa, expanding pediatric indication to treat children ages 3 and older with chronic hepatitis C

Gilead Sciences Inc announced that the US Food and Drug Administration (FDA) has approved an expansio... See more »

June 11, 2021

PharmaLive

Novartis investigational oral therapy iptacopan shows benefit as monotherapy in treatment-nave patients with PNH

Novartis announced new Phase II data for iptacopan (LNP023), an investigational oral treatment for pa... See more »

NexImmune Quarterly and Annual Revenue

Coming soon for NexImmune!

Annual Revenue

NexImmune Acquisitions

No recent acquisitions found related to NexImmune

NexImmune Funding History

Since NexImmune was founded in 2011, it has participated in 8 rounds of funding. In total NexImmune has raised $145.0M. NexImmune's last funding round was on Feb 2021 for a total of $110.0M

ROUND

FUNDING DATE

AMOUNT

INVESTORS

IPO
Feb 2021
$110M

Equity
Jan 2019
$7.8M
Series A
Dec 2017
$21.7M
Debt
Feb 2015
$2M
Debt
Jul 2014
$3M

Total Funding: $145M

Since NexImmune was founded in 2011, it has participated in 8 rounds of funding. In total NexImmune has raised $145.0M. NexImmune's last funding round was on Feb 2021 for a total of $110.0M

NexImmune Investments

No recent investments found related to NexImmune

NexImmune News

February 23, 2021Baltimore Citybizlist

NexImmune Closes IPO

See more »
February 19, 2021The Business Journals: Washington, D.C.

Gaithersburg's NexImmune secures $126.5M from IPO. Here's its plan for the proceeds.

The Montgomery County biotech joins a handful of other local companies to recently debut on the publi... See more »
February 18, 2021Baltimore Citybizlist

NexImmune Closes of Upsized IPO

See more »
February 15, 2021Global University Venturing

News, Data and Events - Global University Venturing

NexImmune priced shares at $17 to raise $110m in an upsized offering, enabling Amgen and Pfizer to ex... See more »
February 12, 2021Seeking Alpha

NexImmune prices upsized initial offering

See more »
February 8, 2021Seeking Alpha

NexImmune Proposes Terms For $75 Million IPO

See more »
January 21, 2021Global University Venturing

NexImmune elects to launch initial public offering -

Johns Hopkins University's oncology therapy developer NexImmune has filed to raise up to $86.3m in an... See more »

NexImmune Press Releases

October 6, 2020GlobeNewswire

First Patient Dosed in NexImmune Phase 1/2 Clinical Trial of NEXI-002 in Multiple Myeloma

With the start of its second clinical trial, NexImmune expands development of its unique non-genetica... See more »
December 19, 2019centralcharts

NexImmune Receives IND Clearance for Phase 1/2 Trial in Relapsed / Refractory Multiple Myeloma

IND clearance enables commencement of clinical trial to evaluate NEXI-002 in Multiple Myeloma patient... See more »
October 31, 2019centralcharts

NexImmune Receives IND Clearance for Phase 1/2 Trial in Acute Myeloid Leukemia / Myelodysplastic Syndrome

IND clearance enables commencement of clinical trial to evaluate NEXI-001 in AML/MDS patients with re... See more »
June 4, 2019GlobeNewswire

NexImmune Management to Present at the Jefferies Healthcare Conference

GAITHERSBURG, Md., June 04, 2019 (GLOBE NEWSWIRE) -- NexImmune, an emerging leader in the field of an... See more »
April 5, 2019streetinsider

NexImmune Management to Present at Upcoming Conferences

NexImmune, an emerging leader in the field of antigen-directed immunotherapy, today announced that Sc... See more »
April 5, 2019centralcharts

NexImmune Management to Present at Upcoming Conferences

NexImmune, an emerging leader in the field of antigen-directed immunotherapy, today announced that Sc... See more »
December 11, 2018centralcharts

NexImmune Granted Key US Patent for Core E+E Technology

“Using our proprietary E+E technology to generate antigen-specific T cells represents a uniquely diff... See more »

Social Media

NexImmune Headquarters

9119 Gaither Road

Gaithersburg, Maryland20877

301-825-9810

Driving Directions »

Trending Companies

NexImmune Summary

ABOUT

Overview

NexImmune researches, develops and commercializes T cell-based immunotherapies for the treatment of cancer. NexImmune was founded in 2011. NexImmune's headquarters is located in Gaithersburg, Maryland, USA 20877. It has raised 145.0M in 8 rounds. The ...

CEO

NexImmune's CEO, Scott P. Carmer, currently has an approval rating of 85%. NexImmune's primary competitors are BMS, Novartis & Gilead.

Frequently Asked Questions about NexImmune

  1. When was NexImmune founded?

    NexImmune was founded in 2011

  2. Who is NexImmune's CEO?

    NexImmune's CEO is Scott P. Carmer

  3. How much revenue does NexImmune generate?

    NexImmune generates $ < 1M in revenue

  4. How much funding does NexImmune have?

    NexImmune has historically raised $145M in funding

  1. Where is NexImmune's headquarters?

    NexImmune's headquarters is in Gaithersburg Maryland, USA

  2. How many employees does NexImmune have?

    NexImmune has 44 employees

  3. What sector does NexImmune operate in?

    NexImmune is in Biotechnology, Pharmaceuticals

  4. Who are NexImmune's competitors?

    NexImmune's top competitors are BMS, Novartis, Gilead
Stay up-to-date with the latest news on NexImmune

© 2021 Owler, Inc.